Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas by Moreno-Bueno, Gema et al.
Research Article
LOXL2 in metastatic basal-like breast carcinomas
528Lysyl oxidase-like 2 (LOXL2), a new regulator
of cell polarity required for metastatic
dissemination of basal-like breast carcinomasGema Moreno-Bueno1,2*, Fernando Salvador1, Alberto Martı´n1, Alfredo Florista´n1, Eva P. Cuevas1,
Vanesa Santos1, Amalia Montes1, Saleta Morales1, Maria Angeles Castilla3, Alejandro Rojo-Sebastia´n2,
Alejandra Martı´nez4, David Hardisson4, Katalin Csiszar5, Francisco Portillo1, He´ctor Peinado1y,
Jose´ Palacios3, Amparo Cano1**Keywords: basal-like carcinomas; breast
cancer; EMT; LOXL2; metastasis
DOI 10.1002/emmm.201100156
Received December 03, 2010
Revised June 06, 2011
Accepted June 07, 2011(1) Departamento de Bioquı´mica, UAM, Instituto de In
dicas ‘‘Alberto Sols’’, CSIC-UAM, IdiPAZ, Institu
Sanitaria La Paz, Madrid, Spain
(2) MD Anderson Cancer Center Madrid, Madrid, Spain
(3) Unidad de Gestio´n Clı´nica de Anatomı´a Patolo´
Patologı´a Molecular del Ca´ncer, Hospital Virgen de
Biosanitario de Sevilla, Sevilla, Spain
(4) Departamento de Anatomı´a Patolo´gica. Hospital La
de Investigacio´n Sanitaria La Paz, Madrid, Spain
(5) John A Burns School of Medicine, University of Haw
*Corresponding author: Tel: þ34 91 4976798; Fax: þ
E-mail: gmoreno@iib.uam.es
**Corresponding author: Tel: þ34 91 4975400; Fax: þ
E-mail: acano@iib.uam.es
y Present address: Department of Pediatrics, Weill Medi
University, 515E 71st Street, New York 10021, USA
 2011 EMBO Molecular MedicineBasal-like breast carcinoma is characterized by the expression of basal/
myoepithelial markers, undifferentiated phenotype, highly aggressive behaviour
and frequent triple negative status (ESR, PR, Her2neu). We have previously
shown that epithelial–mesenchymal transition (EMT) occurs in basal-like breast
tumours and identified Lysyl-oxidase-like 2 (LOXL2) as an EMT player and poor
prognosis marker in squamous cell carcinomas. We now show that LOXL2 mRNA is
overexpressed in basal-like human breast carcinomas. Breast carcinoma cell lines
with basal-like phenotype show a specific cytoplasmic/perinuclear LOXL2 expres-
sion, and this subcellular distribution is significantly associated with distant
metastatic incidence in basal-like breast carcinomas. LOXL2 silencing in
basal-like carcinoma cells induces a mesenchymal-epithelial transition (MET)
associated with a decrease of tumourigenicity and suppression of metastatic
potential. Mechanistic studies indicate that LOXL2 maintains the mesenchymal
phenotype of basal-like carcinoma cells by a novel mechanism involving tran-
scriptional downregulation of Lgl2 and claudin1 and disorganization of cell
polarity and tight junction complexes. Therefore, intracellular LOXL2 is a new
candidate marker of basal-like carcinomas and a target to block metastatic
dissemination of this aggressive breast tumour subtype.vestigaciones Biome´-
to de Investigacio´n
gica and Grupo de
l Rocı´o-IBIS, Instituto
Paz-IdiPAZ, Instituto
aii, Honolulu, HI, USA
34 91 5854401;
34 91 5854401;
cal College of CornellINTRODUCTION
Breast carcinomas represent a highly heterogeneous tumour
family in which different subtypes have been established. To
date, histological grading, lymph node dissemination, hormone
receptor status, expression of ErbB2neu and some additional
markers are the most relevant criteria used to clinically classify
breast carcinomas (Tavassoli & Deville, 2003). Nevertheless,
the present classification does not allow discrimination of
patients with increased metastatic and/or local recurrence risk
or those that develop therapeutic resistance. Results of gene
profiling studies performed during the last decade have allowed
a new molecular classification of breast tumours with potential
clinical impact for breast cancer diagnosis and personalized
treatment. The molecular classification of breast tumoursEMBO Mol Med 3, 528–544 www.embomolmed.org
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Gema Moreno-Bueno et al.include: (i) luminal type (luminal A, luminal B subtypes)
characterized by the expression of luminal markers and estrogen
(ESR) and/or progesterone (PR) receptors; (ii) ErbB2neu type,
exhibiting overexpression of the neu oncogene and other related
genes; (iii) the normal-like group considered very similar to non-
tumoural tissue, and (iv) basal-like type (Perou et al, 2000; Sorlie
et al, 2001, 2003). Basal-like tumours are characterized by
the expression of basal/myoepithelial markers (including
cytokeratin 5/6, epidermal growth factor receptor and p63,
among others) and they are frequently negative for ESR, PR and
ErbB2neu expression (triple negative) (Nielsen et al, 2004;
Rakha et al, 2007). Studies in a large collection of breast
carcinoma cell lines have confirmed the molecular classification
and extended it into two further sub-classes: the basal A
subclass, with a mixed luminal/basal phenotype and the basal
B subclass exhibiting mesenchymal-like characteristics (Blick
et al, 2008; Charafe-Jauffret et al, 2006; Neve et al, 2006).
Recently, a new tumour subtype, known as claudin-low
tumours, has been described, which apparently discriminates
metaplastic breast cancers from other breast tumour subtypes.
These tumours are characterized by low expression of claudin 4
and 7 and high levels of stem cell markers (CD44high/CD24low)
(Hennessy et al, 2009).
Epithelial–mesenchymal transition (EMT), an essential
process in development, has been established as a key event
for dissociation of carcinoma cells from the primary tumours
concomitant to the acquisition of cell migration that provides
tumour cells with the ability to invade into the adjacent tissues
(Thiery et al, 2009). In addition, EMT is considered to be
relevant for other stages of the metastatic cascade such as
intravasation or extravasation (Polyak &Weinberg, 2009). EMT
is currently considered as a focal and transient event occurring
at specific tumour regions and being perhaps more relevant to
specific tumour types (Peinado et al, 2007; Polyak & Weinberg,
2009; Thiery et al, 2009).
Several transcription factors have been described during the
past decade as EMT inducers, including members of the Snail,
bHLH and ZEB families (Peinado et al, 2007; Moreno-Bueno
et al, 2008). A large amount of information has been
accumulated on the plethora of signaling pathways that
modulate their expression both in development and tumour
progression (Peinado et al, 2007; Thiery et al, 2009). Signifi-
cantly, post-transcriptional regulatory mechanisms of EMT
inducers have also been uncovered, including miRNA and non-
coding RNA regulation of ZEB factors (Brabletz & Brabletz,
2010; Cano & Nieto, 2008) as well as post-translational
modifications of Snail1 influencing protein stability and
repression function (MacPherson et al, 2010; Yook et al,
2005; Zhou et al, 2004). Indeed, we have previously described
that Snail1 is regulated by lysyl oxidase-like 2 (LOXL2), which
increases Snail1 protein levels contributing to E-cadherin
repression and EMT induction (Peinado et al, 2005). LOXL2
is a member of the lysyl oxidase (LOX) family, constituted by
five members, the prototypical LOX and four related members,
lysyl oxidase-like (LOXL1-4). All LOX members share a highly
conserved carboxy terminal catalytic domain required for the
oxidative deamination of peptidyl-lysine residues in substrateswww.embomolmed.org EMBO Mol Med 3, 528–544to generate reactive aldehyde groups that initiate covalent inter
and intramolecular crosslinks (Csiszar, 2001; Lucero & Kagan,
2006). LOX and LOXL1 are required for proper extracellular
matrix assembly and homeostasis and cardiovascular system
development (Maki et al, 2002; Liu et al, 2004). LOX and the
LOX-like proteins have also been implicated in tumourigenesis
(Lucero & Kagan, 2006; Maki, 2009; Payne et al, 2007) and a
relevant role for LOX in establishment of the pre-metastatic
niche has been recently described (Erler et al, 2009). LOXL2 has
been previously recognized for its role in invasion of breast
carcinoma cells (Akiri et al, 2003; Hollosi et al, 2009;
Kirschmann et al, 2002) and its transcripts are associated with
poor clinical outcome in lymph-node negative (N0) breast
adenocarcinomas (Peinado et al, 2008) and with metastasis in
estrogen receptor negative breast tumours (Barker et al, 2011).
However, the role of LOXL2 in specific subtypes of breast
carcinomas has not yet been established.
In this study, we show that LOXL2 is overexpressed in basal-
like breast carcinomas. Analyses in a collection of human breast
carcinoma cells demonstrated that LOXL2 is only expressed in
cell lines with a basal-like phenotype in a cytoplasmic and
perinuclear pattern. Interestingly, this subcellular distribution of
LOXL2 is significantly associated with increased metastasis
incidence in human basal-like carcinomas in a large series of
grade 3 breast tumours. Indeed, the loss-of-function studies
indicate that LOXL2 expression is required for cell invasion,
tumour growth and lung metastasis of basal-like breast
carcinoma cells. Interestingly, the action of LOXL2 in basal
carcinoma cells is apparently independent of Snail1 and
E-cadherin modulation, but affects the expression and organiza-
tion of tight junction and cell polarity complexes by a novel
mechanism involving transcriptional downregulation of cell
polarity (Lgl2) and tight junction (claudin1) genes. These data
strongly support the participation of intracellular LOXL2 in the
maintenance of the mesenchymal phenotype and metastatic
potential of basal-like carcinomas. Importantly, the results
presented here indicate that LOXL2 is a new marker and a
potential therapeutic target of metastatic basal-like breast
tumours.RESULTS
Gene expression analyses of grade 3 breast carcinomas
identify LOXL2 as a marker of basal-like tumours
To identify the molecular signature associated to highly
aggressive breast tumours an expression profile analysis was
performed in a sample of 58 grade 3 infiltrative ductal
carcinomas (IDC). After processing the arrays data, unsuper-
vised hierarchical clustering sub-classified the samples into two
clusters. The main cluster included 43 tumours that express ESR
and PR receptors, some luminal markers and/or Her2neu
indicating that this cluster included the luminal and Her2neu
tumours and was defined as a non-basal breast carcinoma
cluster (Supporting Information Fig S1A). The second cluster
contained 15 tumours lacking expression of hormone receptors
and the Her2neu oncogene, thus representing the basal-like 2011 EMBO Molecular Medicine 529
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530tumours (Supporting Information Fig S1A). A supervised
analysis identified a set of 311 genes able to classify the non-
basal and basal-like tumours with a FDR <0.2 (Fig 1A). Around
23% of the genes represent genes previously characterized by
their expression in luminal and basal/mesenchymal breast
cancer cells (Charafe-Jauffret et al, 2006; Neve et al, 2006)
(Fig 1B; Supporting Information Table S1). The basal-like
tumours showed very low levels of ESR, PR and Her2neu
transcripts as compared to the mean values obtained for the
non-basal tumours (Fig 1C), indicating that the basal-like cluster
indeed contains the triple negative tumours. In addition, the
basal-like tumours showed upregulated expression of typical
basal genes, like cytokeratins 5/6 (Fig 1C) as well as caveolin1
and p63 (Fig 1B; Supporting Information Table S1). To evaluate
the biological relevance of the identified ‘‘basal-like breast
signature’’ (BBS), we tested for its presence in several public
breast cancer databases and found that it defines the basal-like
tumours in the van ’t Veer et al (2002) and Wang et al (2005)
series, as well as basal breast cell lines in the Charafe-Jauffret
et al (2006) series (Supporting Information Fig S1B).Figure 1. LOXL2 mRNA is upregulated in basal like carcinoma tumours.
A. Supervised analysis of microarray expression profile of grade 3 breast carcinom
(B, n¼15, right column, purple) and non-basal (NB, n¼43, left column, yello
B. Representative selection of genes differentially upregulated (red) and downreg
expressed in basal and luminal breast carcinomas (Charafe-Jauffret et al, 200
C. Mean expression values of ESR, PGR, ErbB2 (HER2), and cytokeratin 5 (KRT5) m
D. Mean expression value of LOXL2 mRNA detected in the microarray analysis in
E. Quantitative RT-PCR analyses of LOXL2 expression in breast carcinomas (n¼46
non-basal (n¼28) tumours.
 2011 EMBO Molecular MedicineWe have previously reported that EMT occurs in basal-like
breast tumours (Sarrio et al, 2008) and identified LOXL2 as an
EMT regulator (Peinado et al, 2005). In agreement with this, we
found that LOXL2 mRNA was upregulated in the basal-like
cluster (Fig 1B) with a mean of around twofold increased
expression over the non-basal tumours (Fig 1D). qRT-PCR
analysis of LOXL2 performed in 46 tumours (28 with non-basal
and 18 with basal-like phenotype) confirmed that LOXL2
expression was increased in basal-like tumours by a mean of
5.0-fold compared to non-basal tumours (Fig 1E). Interestingly,
analyses of LOXL2 expression in public databases indicated
that overexpression of LOXL2 mRNA associates with basal-like
breast tumours and/or to distant metastasis in several
independent series (Supporting Information Fig S2A and B).
This finding is also in agreement with our previous observation
that LOXL2 mRNA overexpression is associated with decreased
overall survival in N0 breast tumours (Peinado et al, 2008)
and with a recent report showing increased LOXL2 mRNA
associated with metastasis in ER- breast tumours from the NKI
database (Barker et al, 2011).as (n¼58) with a FDR 0.2. Tumours were classified in two groups: basal-like
w).
ulated (green) in basal-like tumours. The previous identification of the genes
6) is indicated at the top.
RNAs from the microarray data in basal and non-basal groups.
non-basal and basal-like tumours.
) identified greater than fivefold increased expression in basal (n¼18) versus
EMBO Mol Med 3, 528–544 www.embomolmed.org
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Once shown that LOXL2 was preferentially expressed in basal-
like tumours, we analysed a series of breast carcinoma cell lines
representing basal, luminal and ErbB2þ subtypes (Charafe-
Jauffret et al, 2006; Neve et al, 2006) and found that LOXL2
mRNA expression was only detected in the basal-like carcinoma
cell lines MDA-MB-231, BT549 and in the non-tumourigenic
human mammary HBL100 (Fig 2A); the cell lines that lacked
ESR/PR/Her2neu expression and exhibited a mesenchymalFigure 2. LOXL2 is expressed in basal-like breast cell lines and its silencing in
A. Quantitative RT-PCR analyses of LOXL2 expression in the indicated breast cell li
and HBL100 cells; no LOXL2 transcripts were detected in luminal MCF7 and
B. Western blot of whole cell extracts for LOXL2 expression in the indicated cel
C. Immunofluoresce staining for LOXL2 in the indicated cell lines; see the cytoplas
non-basal SkBR3 cells. Bar, 50mm.
D. Quantitative RT-PCR analyses of LOXL2 expression in parental (wt), control (s
shLOXL2 in MDA-MB-231 cells.
E. Western blots for LOXL2, E-cadherin (E-Cad) and Snail1 expression in parental M
included as a negative and positive control for LOXL2, Snail1 and E-cadherin
F. Western blot for N-cadherin and cadherin11 in the indicated cell lines. a-tub
G. Phase-contrast images of MDA-MB-231-shEGFP and -shLOXL2 (clone C1) cell
H. Cell motility of MDA-MB-231-shEGFP and -shLOXL2 (clone C1) cells analysed
I. Invasion assay on collagen type IV of parental MDA-MB-231 (WT) cells and s
experiments performed in triplicate samples; bars, standard deviation (s.d.)
J. Proliferation assay by incorporation of BrdU of parental MDA-MB-231 cells a
experiments performed in quadruple samples; bars, s.d; n.s, not statistically s
www.embomolmed.org EMBO Mol Med 3, 528–544phenotype (Blick et al, 2008; Charafe-Jauffret et al, 2006;
Neve et al, 2006). In contrast, no detectable levels of LOXL2
transcripts were present in the luminal (MCF7) and Her2neuþ
(SkBR3, BT474) breast carcinoma cell lines (Fig 2A). Western
blot analyses confirmed the expression of LOXL2 in the basal-
like cell lines (Fig 2B) and immunofluorescence analyses
showed the intracellular localization of LOXL2 with an intense
punctuate cytoplasmic and/or perinuclear pattern in basal
carcinoma cells (Fig 2C) as we have previously described induces MET.
nes; high expression levels were detected in basal breast MDA-MB-231, BT549
ErbB2þ BT474 and SkBR3 cells.
l lines. B, basal; NB, non-basal.
mic and perinuclear stain in basal carcinoma cells and the absence of stain in
hEGFP) and two independent clones (C1, C2) generated after transfection of
DA-MB-231 cells and in shEGFP- and shLOXL2-derived clones. MCF7 cells were
expression, respectively.
ulin (a-Tub) was used as a loading control in (B), (E) and (F).
s: 10 magnification.
by a barrier assay. Images were taken at 0 h (a, b) and 48 h (c, d).
hEGFP- and shLOXL2-derived clones; results represent the mean of two
nd shEGFP and shLOXL2-derived clones; results represent the mean of two
ignificant.
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532other cell systems (Peinado et al, 2005, 2008). As expected, no
expression of LOXL2 was detected by immunofluorescence in
non-basal carcinoma cells (Fig 2C; and data not shown).
LOXL2 silencing in basal carcinoma cell lines reduces
invasiveness and cell motility
To obtain further insights into the role of LOXL2 in basal-like
carcinomas, we generated stable basal breast carcinoma MDA-
MB-231 cells in which LOXL2 was silenced. The MDA-MB-231-
shLOXL2 clones showed significantly reduced LOXL2 mRNA
(Fig 2D) and LOXL2 protein levels (Fig 2E), without significant
changes in LOXL4 (Supporting Information Fig S3A), the other
LOXL member expressed by MDA-MB-231 cells (Peinado et al,
2005). MDA-MB-231-shLOXL2 cells exhibited a more epithelial
phenotype compared to control MDA-MB-231-shEGFP cells
(Fig 2G). However, only a very modest re-expression of E-
cadherin was detected by Western blot after LOXL2 silencing
(Fig 2E). No expression of P-cadherin could be detected (data
not shown) but MDA-MB-231-shLOXL2 cells maintained notice-
able protein levels of N-cadherin and cadherin 11 (Fig 2F). On
the other hand, Snail1 protein levels were not significantly
modified in MDA-MB-231-shLOXL2 cells compared to controls
(Fig 2E). Importantly, silencing of LOXL2 resulted in a marked
decrease in migratory ability and motility of MDA-MB-231 cells
as determined by barrier (Fig 2H) and wound healing assays
(data not shown). Furthermore, LOXL2 silencing resulted in a
highly significant decrease of the invasion capacity of MDA-MB-
231 cells (Fig 2I) while their proliferation in bi-dimensional
cultures was not significantly affected (Fig 2J), in agreement
with a recent report (Barker et al, 2011).
To ascertain whether the marked effect of LOXL2 silencing on
the phenotype and migratory capacity was restricted to MDA-
MB-231 cells or rather represents a general effect on basal cells,
stable knockdown of LOXL2 was also performed in BT549 and
HBL100 basal cell lines (Supporting Information Fig S3B).
Again, LOXL2 silencing in both of these cell lines resulted in a
marked reversion towards the epithelial phenotype that was
particularly evident in high density cultures of BT549-shLOXL2
cells (Supporting Information Fig S3C). LOXL2 silencing also led
to a dramatic inhibition of cell motility in BT549 and HBL100
cells (Supporting Information Fig S3D and E) and suppression of
invasiveness in BT549 cells (Supporting Information Fig S4C).
Noteworthy, no re-expression of E-cadherin was detected in
BT549 or HBL100 cells after LOXL2 silencing (Supporting
Information Fig S3B), but BT549-shLOXL2 cells maintained
noticeable N-cadherin and cadherin11 levels (Supporting
Information Fig S4A). Moreover, BT549 cells do not express
endogenous Snail1 and remained unchanged after LOXL2
silencing (Supporting Information Fig S4A). In addition,
reorganization of F-actin and downregulation of vimentin is
observed after LOXL2 silencing in BT549 cells (Supporting
Information Fig S4B). These results indicate that LOXL2
silencing induces a MET-like process in basal cell lines
associated with decreased invasive and migratory properties.
They are also in concordance with our previous observation and
those by other groups showing that ectopic expression of LOXL2
in luminal MCF7 cells induces a mesenchymal-like phenotype 2011 EMBO Molecular Medicineand migratory and invasive potential (Fig 3B; Akiri et al, 2003;
Hollosi et al, 2009). The present results support that LOXL2 is
involved in the maintenance of the mesenchymal phenotype in
basal carcinoma cells.
LOXL2 modulates focal adhesion, tight junctions and cell
polarity complexes in a dual fashion in basal carcinoma cells
Previous studies have reported the positive modulation of FAK
and Src pathways by LOXL2 in gastric carcinoma cells (Peng
et al, 2009), while a negative modulation of the FAK pathway
has been reported for the LOX pro-peptide in breast carcinoma
cells (Zhao et al, 2009). We analysed the influence of LOXL2 on
FAK and Src pathways and focal adhesion organization after
LOXL2 silencing in MDA-MB-231 cells, in parallel with analyses
in the gain of function system, MCF7-LOXL2-V5 cells (Fig 3B),
we recently described (Hollosi et al, 2009). Control MDA-MB-
231 cells presented high levels of activated P-FAK and P-Src that
were reduced in MDA-MB-231-shLOXL2 cells (Fig 3C and D); on
the contrary, control MCF7 cells showed undetectable P-FAK
and very low levels of P-Src that were not apparently changed in
MCF7-LOXL2 cells (Fig 3C). The influence of LOXL2 on focal
contact organization was then analysed by confocal immuno-
fluorescence of P-FAK, vinculin and F-actin (Fig 3A). Control
MDA-MBA-231 cells showed prominent focal contacts on
membrane extensions resembling filopodia as well as on the
lower cell surface area with clear co-localization of P-FAK,
vinculin and F-actin bundles (Fig 3A, a–d). In striking contrast,
MDA-MBA-231-shLOXL2 cells exhibited low and diffuse stain-
ing of P-FAK and vinculin, and showed very few and small focal
contacts organized apparently only at the cell periphery (Fig 3A,
e–h). In agreement with their epithelial phenotype, MDA-MBA-
231-shLOXL2 cells also showed strongly decreased F-actin stress
fibres and apparent reorganization to cortical F-actin as
compared to control cells (Fig 3A, compare panels c and g).
Interestingly, focal adhesion and F-actin organization of MCF7
cells was alike to that of MDA-MBA-231-shLOXL2 cells
(Fig 3A, i–l), while MCF7-LOXL2 cells showed increased focal
contact organization at cell membrane extensions resembling
filopodia (Fig 3A, m–p), thus being more similar to the pattern
observed in control MDA-MBA-231 cells. Additional analyses of
P-Src and focal contact organization corroborated these findings
(Supporting Information Fig S5). These results indicate that
LOXL2 positively modulates the FAK and Src signaling path-
ways and focal contact organization of basal-like carcinoma
cells that can contribute to the cell migratory behaviour.
The striking induction of MET by LOXL2 silencing in basal-
like carcinoma cells led us to analyse in further detail the
expression/organization of cell junctions. As demonstrated
above, the cell phenotype induced by LOXL2 silencing in basal-
like carcinoma cells was apparently independent of E-cadherin
(Fig 2E, Supporting Information Fig S3B). Indeed, confocal
analyses indicated that the low E-cadherin protein levels
detected in MDA-MBA-231-shLOXL2 cells were not properly
organized at cell–cell contacts in most adherent cells
(Fig 4A, a,b). In contrast, MCF7-LOXL2 cells, although showing
reduced E-cadherin levels (Supporting Information Fig S6C),
organized E-cadherin at cell–cell contacts in most adherent cellsEMBO Mol Med 3, 528–544 www.embomolmed.org
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Figure 3. LOXL2 induces FAK activation and organization of focal contacts.
A. Confocal immunofluoresce images for P-FAKY397 (green), vinculin (red) and F-actin (white) organization in control MDA-MB-231-shEGFP (a–d), -shLOXL2
(clone C1) (e–h), parental MCF7 (i–l) and MCF7-LOXL2 (m–p) cells. Merged images are shown at the right panels. Bars, 50mm.
B. Phase contrast images of parental MCF7 (left) and MCF-LOXL2-V5 (right) cells.
C. Western blot analyses of Src and FAK activation and total expression levels in the indicated cell lines. a-tubulin (a-tub) was used as a loading control.
D. Ratio of P-Src/Src and P-FAK/FAK levels from densitometry analysis of the blot shown for MDA-MB-231 cells in (C). Similar results were obtained in two
independent experiments.in a pattern similar to that present in parental MCF7 cells
(Fig 4B, a,b). The expression and organization of other adhesion
complexes, in particular tight junctions, was then investigated
in both cell systems. Western blot analyses indicated increased
expression of claudin1 in MDA-MBA-231-shLOXL2 cells while
the soluble ZO1 protein levels decreased slightly compared to
parental cells (Supporting Information Fig S6A). On the other
hand, strongly decreased expression of ZO1 was detected in
MCF7-LOXL2 cells compared to parental MCF7 cells, while no
expression of claudin1 was detected in parental or MCF7-LOXL2
cells (Supporting Information Fig S6A). Importantly, confocal
immunofluorescence analyses showed that ZO1 and claudin1
were properly organized at cell–cell contacts at the upper lateral
membrane in MDA-MBA-231-shLOXL2 cells (Fig 4A, d,f and
insets) in a pattern strikingly similar to that present for ZO1 in
MCF7 cells (Fig 4B, f and inset). In agreement with these
observations, ZO1 and claudin1 were fully disorganized or not
detected in MDA-MB-231-shEGFP and MCF7-LOXL2 cellswww.embomolmed.org EMBO Mol Med 3, 528–544(Fig 4A/B, c,e). Together, these data indicate a negative role
for LOXL2 in the expression and organization of tight junction
complexes of basal-like carcinoma cells.
Apico-basal polarity is an essential property of epithelial cells
that is lost during EMT (Dow & Humbert, 2007; Moreno-Bueno
et al, 2008). Several recent reports have shown the influence of
EMT factors, like ZEB1 or Snail, in the transcriptional repression
of cell polarity components (Aigner et al, 2007; Spaderna et al,
2008; Whiteman et al, 2008). To obtain further insights into the
regulation of EMT mediated by LOXL2 in basal-like carcinoma
cells, we next studied the expression and organization of cell
polarity components. We choose to analyse Par3 and Lgl2
molecules as representative of the Par and Scribble cell polarity
complexes, respectively (Dow & Humbert, 2007; Moreno-Bueno
et al, 2008). The protein expression levels of Par3 and Lgl2
strongly increased in MDA-MBA-231-shLOXL2 compared to
control cells, while they decreased significantly in MCF7-LOXL2
cells compared to parental cells (Supporting Information 2011 EMBO Molecular Medicine 533
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Figure 4. LOXL2 silencing in basal carcinoma cells induces expression and reorganization of tight junctions and cell polarity complexes.
A, B. Confocal immunofluorescence analyses in MDA-MB-231-shEGFP and -shLOXL2 (Clone 1) (A) and MCF7 and MCF-LOXL2 (B) cells for E-cadherin (a, b);
claudin1 (c, d), ZO1, (e, f), Par3 (g, h) and Lgl2 (i, j). x–y maximal projections are shown for E-cadherin (A, B) and claudin1 (B) stain; z–x planes are shown in the
rest of panels. Insets in panels d, f, h, j, indicate enlarged areas (right) showing positive immunostaining along the lateral membrane. Colour scale indicates
the intensity of staining from basal (bottom, purple) to apical (top, red) localization. Bars, 50mm.
534Fig S6B). More importantly, confocal immunofluorescence
analyses showed weak cytoplasmic and/or nuclear stain of
Par 3 and Lgl2, respectively, in control MDA-MBA-231-shEGFP
cells (Fig 4A, g,i). Strikingly, both Lgl2 and Par3 stained strongly
and organized at the upper lateral region in MDA-MBA-231-
shLOXL2 cells (Fig 4A, h,j and insets). Interestingly, the reverse
situation was observed in MCF7 cell system, in which the
organized expression of Par3 and Lgl2 containing cell polarity
complexes of parental cells (Fig 4B, h,j and insets) was fully lost
in MCF7-LOXL2 cells (Fig 4B, g,i). These results strongly
support that LOXL2 negatively modulates the expression
and organization of cell polarity complexes in basal-like
carcinoma cells.
The punctuate cytoplasmic and perinuclear stain of LOXL2
detected in basal breast cells (Fig 2C) suggested its association
with the Golgi network and vesicle trafficking that could
affect the transport and/or organization of cell–cell adhesion
and polarity complexes. Confocal immunofluorescence 2011 EMBO Molecular Medicineanalyses showed that intracellular LOXL2 associates to the
trans-Golgi network as demonstrated by its colocalization with
the GM130 Golgi marker in both MDA-MB-231 control and
MCF7-LOXL2 cells (Supporting Information Fig S7). This
latter analysis also indicated that the overall organization of
the trans-Golgi network is not disturbed by the expression of
LOXL2 or its silencing (Supporting Information Fig S7), thus
discarding an overall effect of LOXL2 on intracellular Golgi
trafficking.
LOXL2 represses claudin1 and Lgl2 promoters independently
of Snail1 and of its enzymatic activity
The above results led us to further investigate the mechanisms
underlying LOXL2 mediated downregulation of tight junctions
and cell polarity complexes. To this end, we chose claudin1 and
Lgl2 as representative components of tight junctions and cell
polarity complexes, respectively, whose expression has been
previously shown to be downregulated by EMT factors, likeEMBO Mol Med 3, 528–544 www.embomolmed.org
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Gema Moreno-Bueno et al.Snail1/Snail2 and/or ZEB1 (Aigner et al, 2007; Martinez-Estrada
et al, 2006; Ohkubo and Ozawa, 2004; Spaderna et al, 2008). RT-
PCR analyses of claudin1 and Lgl2 transcripts showed an inverse
association with LOXL2 expression in MDA-MB-231 cells
(Fig 5A). We then speculated that LOXL2 could downregulate
claudin1 and Lgl2 gene transcription. Promoter assays indicated
that the activity of claudin1 and two independent Lgl2
promoters were upregulated in MDA-MBA-231-shLOXL2 cells
compared to parental and control shEGFP cells (Fig 5B),
supporting a negative influence of LOXL2. Indeed, transient
promoter assays indicated that LOXL2 represses the activity of
both Lgl2 promoter constructs in a dose-dependent fashion up to
60% (Fig 5C). The activity of the claudin1 promoter was alsoFigure 5. Claudin1 and Lgl2 are transcriptionally repressed by LOXL2.
A. RT-PCR of claudin1 and Lgl2 transcripts in the indicated cell lines. GAPDH
B. Activity of claudin1 and Lgl2 promoters in parental MDA-MB-231 cells (WT) a
as relative luciferase units (RLU) and normalized to the activity detected i
C. Activity of the two Lgl2 promoters in HEK293T cells in the presence of the i
obtained in the presence of control pcDNA3 vector (100 ng).
D.–F. Activity of claudin1 (D) and the two Lgl2 promoters (E, F) in the presence of th
that obtained in the presence of control pcDNA3 vector (100 ng). Results in (
experiments performed in quadruple samples. (p0.05, p 0.005, p
www.embomolmed.org EMBO Mol Med 3, 528–544repressed by LOXL2 to about 40% (Fig 5D), a lower potency
than that previously shown by Snail1 (up to 60%) (Fig 5D;
Martinez-Estrada et al, 2006). Interestingly, the repressive
action of LOXL2 on the claudin1 and Lgl2 promoters was
independent of Snail1 and, surprisingly, also of the LOXL2
catalytic activity since a LOXL2 deletion mutant lacking the
catalytic domain (DLOXL2; aa 548–688 deleted) showed the
same repressor potency as the wild type LOXL2 on either
promoter (Fig 5D–F). Taken together, these data indicate that
LOXL2 downregulates tight junction and cell polarity complexes
in basal-like carcinoma cells at the transcriptional level by a
mechanism independent of Snail1 and LOXL2 enzymatic
activity.is used as a loading control.
nd in control shEGFP and shLOXL2 (clone C1) cells. The activity was determined
n WT cells for each promoter.
ndicated amounts (ng) of LOXL2. The activity, as RLU, was normalized to that
e indicated expression vectors (50 ng). The activity, as RLU, was normalized to
B) to (F) represent the mean þ/ s.d of three (B–D) and two (E, F) independent
0.001)
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536Silencing of LOXL2 reduces tumour growth and inhibits local
recurrence and metastatic capacity of basal breast
carcinoma cells
The former results demonstrated the participation of LOXL2 in
basal-like carcinoma phenotype. To obtain further information
about the biological function of LOXL2 in basal breast
carcinomas, we orthotopically injected control MDA-MB-231-
shEGFP and MDA-MB-231-shLOXL2 cells into the mammary fat
pad of nude mice and analysed their tumourigenic potential.Figure 6. LOXL2 knockdown induces decreased tumourigenicity and inhibitio
A. Comparative tumourigenic analysis of control MDA-MB-231-shEGFP and shLOX
pad of female nude mice; tumour volume was measured every 4 days after injec
bars, s.d.
B. Local recurrence determined by the appearance of tumours at the mammary
C. Representative bioluminescence images of mice intravenous (i.v.) injected wi
(bottom) obtained at 3, 6 and 9 weeks after tail vein injection. The colour scale r
xenografted mice.
D. Bioluminescence (BLI) plots showing the quantification of the luminescence sig
i.v. injected with control MDA-MB-231TGL-shEGP (black) and two independen
obtained from six injected mice with each cell line.
E. Representative images of hematoxilin and eosin staining of lung sections obta
(b) cells; 10 magnification.
 2011 EMBO Molecular MedicineControl MDA-MB-231-shEGFP cells gave rise to tumours at all
injection sites (4/4) reaching a volume of 0.4 cm3 20 days after
injection (Fig 6A). In contrast, silencing of LOXL2 strongly
reduced the tumour growth potential of MDA-MB-231 cells
requiring 42 days to reach a similar tumour volume while the
tumour incidence remained the same (4/4) (Fig 6A). No
histological differences were detected between control and
shLOXL2 xenografts (data not shown). The influence of LOXL2
silencing on themetastatic burden ofMDA-MB231 cells was alson of lung metastatic capacity of basal MDA-MB-231 cells.
L2 (clone C1) cells. The indicated cell lines were injected into the mammary fat
tion. Data show the mean of four independent mice for each injected cell line;
gland region after 45 days of resection of primary mammary tumours.
th control MDA-MB-231TGL-shEGP (upper) and -shLOXL2 (clone C1) cells
epresents the photon flux (photons per second) emitted from the lung region of
nal, represented as average radiance, emitted as a function of time from mice
t shLOXL2 clones (c1, red; c2, green). Results represent the mean þ/ s.d.
ined from mice i.v. injected with MDA-MB-231TGL-shEGFP (a) and -shLOXL2
EMBO Mol Med 3, 528–544 www.embomolmed.org
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of the primary tumours (1 106 cells/mammary fat pad) after
they reached 0.4 cm3 volume. No lung metastasis could be
detected in nude mice injected with either MDA-MB-231 control
or -shLOXL2 after 4 months, in agreement with the low
spontaneous metastatic capacity reported for the parental cell
line (Minn et al, 2005; Olmeda et al, 2007; Price et al, 1990).
Interestingly, however, local tumour recurrence was detected in
mice injected with control MDA-MB231-shEGFP cells after
45 days of tumour resection but not in mice injected with MDA-
MB231-shLOXL2 cells (Fig 6B), suggesting a role for LOXL2 in
local tumour recurrence.
Experimental metastasis assays were then performed by tail
vein injections of control and MDA-MB231-shLOXL2 cells. To
this end, LOXL2 was silenced in MDA-MB-231-TGL cells
expressing luciferase and GFP (Minn et al, 2005) to allow for
non-invasive bioluminescence analysis. MDA-MB231-TGL cells
were characterized for efficient LOXL2 silencing (Supporting
Information Fig S8A). MDA-MB231-TGL-shLOXL2 cells exhib-
ited a marked epithelial phenotype albeit they lacked E-cadherin
re-expression (Supporting Information Fig S8B and C) as
observed for MDA-MB231-shLOXL2 cells (Fig 2E and G).
Silencing of LOXL2 resulted in a dramatic decrease of lung
colonization of MDA-MB231-TGL cells (Fig 6C and D). Mice
injected with control MDA-MB231-TGL-shEGFP cells started to
show detectable luciferase activity in the lung region 3 weeks
after intravenous injection that steadily increased for up to
9 weeks (Fig 6C and D) when the mice had to be sacrificed. In
contrast, mice injected with MDA-MB231-TGL-shLOXL2 cells
showed a dramatic suppression of lung colonization, as
indicated by the lack of bioluminescent emission in the lung
region up to 12 weeks after injection (Fig 6C and D). Mice
injected with MDA-MB231-TGL-shLOXL2 cells survived in
healthy conditions for up to 3 months after injection at which
time they were sacrificed. Lung inspection at necropsy revealed
macrometastasis in all samples derived from mice injected with
control shEGFP cells, while mice injected with shLOXL2 cells
were devoid of metastatic lung lesions (Fig 6E). These
observations indicate that LOXL2 silencing in MDA-MB231
cells strongly impairs lung tumour homing and/or the efficient
growth of the metastatic lung foci.
LOXL2 expression in breast cancer and its correlation with
clinical and pathological data
To address the biological significance of LOXL2 in human breast
cancer, we analysed a cohort of 195 formalin-embedded grade 3
infiltrative ductal breast carcinomas for LOXL2 expression (see
Supporting Information Table S2, for clinical and molecular
description of the tumour series). We used our home-made,
previously characterized, polyclonal antiserum (herein called
KC) (Fong et al, 2007; Hollosi et al, 2009). This study revealed
intracellular LOXL2 expression in tumour cells with two different
staining patterns, similar to those previously identified in human
squamous cell carcinomas (Peinado et al, 2008): a diffuse and
homogeneous cytoplasmic localization was found in 79.5%
(Fig 7A, b; Supporting Information Table S2), and increased
staining of LOXL2 in the cytoplasm and perinuclear region waswww.embomolmed.org EMBO Mol Med 3, 528–544detected in 20.5% of tumours (Fig 7A, c; Supporting Information
Table S2). The normal mammary gland adjacent to the tumour
area showed a faint cytoplasmic LOXL2 staining, which was
absent inmyoepithelial cells (Fig 7A, a). Interestingly, LOXL2was
not detected in normal and tumoural stroma in the present breast
tumour series, in agreement with our own previous observations
in other tumour types stained with the same antisera (Fong et al,
2007; Hollosi et al, 2009; Peinado et al, 2008). Other recent
studies have reported the expression of extracellular LOXL2 in a
reduced series of breast adenocarcinoma using a different, non-
commercial, anti-LOXL2 antiserum (herein called Arresto)
(Barry-Hamilton et al, 2010). We therefore also stained part of
our breast tumour series (n¼ 84) with the latter antiserum
detecting 47 cases (55.9%) with positive expression of LOXL2
(Supporting Information Table S2); specifically, intracellular
LOLX2 localization was found in 12 cases (14.3% of total), and
intracellular plus stromal distribution of LOXL2 observed in 35
biopsies (41.7%) (Supporting Information Fig S9A b,d; Support-
ing Information Table S2). Interestingly, almost 65% of the cases
with intracellular LOXL2 localization correspond to basal
carcinomas, a similar percentage as the cytoplasmic/perinuclear
stain detected with our home-made antiserum (Supporting
Information Fig S9B). These results corroborate the intracellular
LOXL2 distribution in basal-like breast cancer.
Basal-like breast tumours within the present tumour series
were subclassified according to the established immunohisto-
chemical (IHC) criteria for this tumour subtype (Nielsen et al,
2004; Rakha et al, 2007) (Supporting Information Fig S10 and
Supporting Information Tables S2 and S3). Fifty-four cases
(28%) were classified as basal-like breast tumours and the rest
(n¼ 139, 72%)were considered non-basal tumours (Supporting
Information Table S2). A highly significant statistical correlation
was found between the intense cytoplasmic/perinuclear LOXL2
expression pattern detected with our antiserum and basal-like
tumours (p 0.001; Fig 7B and Supporting Information Table
S3). Comparison of LOXL2 expression with clinico-pathological
parameters showed a significant correlation between the
heterogeneous LOXL2 pattern and negative ESR and/or PR
expression (p 0.001 and p¼ 0.003, respectively; Supporting
Information Table S3). Furthermore, a statistical tendency was
observed between the heterogeneous pattern of LOXL2 expres-
sion and high levels of the proliferationmarker Ki67 (p¼ 0.073),
while no correlation with p53 status was found (Supporting
Information Table S3). The expression of E-cadherin and other
established EMTmarkers in basal-like breast carcinomas (Sarrio
et al, 2008) was also analysed. E-cadherin expression was
detected in a high percentage of the analysed tumours (55 out of
92) and no association with LOXL2 expression was found
(Supporting Information Fig S10 and Table S3). Perinuclear
LOXL2 expression was associated with CK5, EFGR and
cadherin-11 staining in 82.6% (p 0.001), 64% (p 0.001)
and 62% (p¼ 0.045) of the cases, respectively (Supporting
Information Fig S10 and Table S3). In addition, a statistical
tendency was found between heterogeneous LOXL2 and SPARC
expression (p¼ 0.068), further supporting the association of
those markers with basal-like tumours. Importantly, LOXL2
cytoplasmic/perinuclear expression strongly correlated with 2011 EMBO Molecular Medicine 537
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Figure 7. LOXL2 expression is increased in basal-like tumours with a specific cytoplasmic/perinuclear staining pattern and associated to distant
metastasis.
A. Immunohistochemical analysis of LOXL2 in paraffin-embedded grade 3 IDC (n¼195). (a) Weak diffuse stain in normal mammary gland. (b) Diffuse cytosolic
expression pattern in tumour cells; (c) intense cytosolic and perinuclear expression pattern in tumour cells; 40 magnification. Insets in (b) and
(c) show magnification (160) areas (right). See the absence of expression in the normal and tumoural stroma.
B. Correlation between LOXL2 cytoplasmic/perinuclear pattern and the basal-like phenotype and metastasis incidence of grade 3 IDC tumours.
C. Correlation between LOXL2 stain pattern and metastastic incidence in basal-like breast carcinomas.
538distant metastasis incidence (p< 0.001; Fig 7B, Supporting
Information Table S3). From the 54 basal-like tumours, data for
metastasis and LOXL2 pattern were available for 39 samples.
Noteworthy, 18 cases of the basal tumours showed intracel-
lular/perinuclear LOXL2 localization and, among them, 14
(77.8%) were metastatic. On the other hand, only a small
fraction of basal tumours that showed a diffuse LOXL2 pattern
(6 out of 21, 28.6%) displayed distant metastasis. Considering
that a similar number of basal lesions was analysed for the
two LOXL2 staining pattern (18 cytoplasmic/perinuclear and
21 diffuse), we conclude that there is a clear connection between
cytoplasmic/perinuclear LOXL2 staining, basal phenotype and
metastasis risk.DISCUSSION
Basal-like carcinomas are highly aggressive tumours with
visceral metastasis, poor prognosis and a high tendency to
develop chemoresistance (Foulkes et al, 2010; Nielsen et al, 2011 EMBO Molecular Medicine2004; Reis-Filho et al, 2006; Rodriguez-Pinilla et al, 2006). Basal-
like breast carcinomas are presently considered a heterogenous
group that may include the recently identified claudin-low
(Hennessy et al, 2009; Taube et al, 2010), metaplastic tumours
(Reis-Filho et al, 2006), BRCA1-associated tumours and, at least
part of the triple negative tumours (ER/PR/ErbB2neu)
(Foulkes et al, 2010). It is still presently undefined whether
basal-like breast tumours originate from precursor cells distinct
from those of other breast tumour types (Blick et al, 2010;
Foulkes et al, 2010; Hennessy et al, 2009; Korsching et al, 2005;
Shipitsin et al, 2007) or if different entities of basal-like tumours
derive from different precursors, as recently proposed for
the luminal origin of BRCA1-associated basal-like cancers
(Lim et al, 2009; Molyneux et al, 2010). Unfortunately, the
therapeutic targets for basal-like tumours have not been defined
yet hindering the treatment of this specific breast tumour type.
Interestingly, basal-like, as well as the claudin-low subtype and
metaplastic breast tumours have been recently identified by us
and others as likely candidates prone to undergo EMT processes
(Hennessy et al, 2009; Sarrio et al, 2008; Taube et al, 2010).EMBO Mol Med 3, 528–544 www.embomolmed.org
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(Peinado et al, 2005) and defined LOXL2 as a prognostic marker
in larynx squamous cell carcinomas (Peinado et al, 2008).
In this work, we identify LOXL2 as a marker of basal-like
breast tumours and provide functional evidence for its
involvement in the invasion and metastatic dissemination of
basal carcinoma cells. Gene profiling and qRT-PCR analysis of
grade 3 IDC identified a basal-like gene signature that defines
the basal-like tumours in independent public databases from
N0 breast series and in a dataset from breast carcinoma cell
lines (Supporting Information Fig S1B). Notably, LOXL2
mRNAwas highly upregulated in the basal-like cluster identified
in the present study (Fig 1) that we validated in several public
databases (Supporting Information Fig S2A). Furthermore,
the association of LOXL2 expression with basal-like breast
tumours was confirmed in studies using breast cell lines
showing that LOXL2 expression was only observed in those
previously sub-classified as basal B/mesenchymal subtype with
predominant mesenchymal gene expression and enhanced
invasiveness (Blick et al, 2008; Charafe-Jauffret et al, 2006;
Neve et al, 2006). Interestingly, LOXL2 was localized in
a cytoplasmic and perinuclear pattern in basal cells, as we
found in previous studies in LOXL2 overexpressing cells
(Peinado et al, 2005).
Silencing of LOXL2 greatly decreases the migratory and
invasive capacities of basal cell lines (MDA-MB-231 and BT549)
as well as migration of HBL100 cells. These results confirm and
extend the previously proposed pro-invasive role of LOXL2
derived from LOXL2 gain-of-function studies in luminal breast
MCF7 cells (Akiri et al, 2003; Hollosi et al, 2009) and are also in
agreement with recent reports of LOXL2 silencing in MDA-MB-
435 and MDA-MB-231 carcinoma cells (Barker et al, 2011;
Barry-Hamilton et al, 2010). Remarkably, in addition to
inhibition of invasion, LOXL2 knockdown has a significant
inhibitory effect on the tumour growth potential, local
recurrence and, importantly, on the lung metastatic dissemina-
tion of MDA-MB-231 cells. The tumourigenic data obtained in
the present study differ from those recently reported by Barker
and colleagues in which no differences in tumour growth
capacity were detected inMDA-MB-231 cells and even increased
tumour growth was detected in mouse 4T1 breast carcinoma
cells after LOXL2 silencing (Barker et al, 2011). The differences
in MDA-MB-231 cells could be explained by the higher cell dose
injected in the mammary fat pad (1 107) in the latter study that
may erase or attenuate the differences in the tumourigenic
behaviour we observed here between control and shLOXL2 cells
after injecting a lower cell dose (1 106). On the other hand,
the reported data on 4T1 cells could unfortunately not be
corroborated, since in our hands endogenous LOXL2 transcripts
were not detected in 4T1 cells obtained from the ATCC
collection (data not shown), thus precluding further studies
on the influence of LOXL2 silencing in these cells. In this regard,
it is also worthmentioning that significant differences in tumour
growth after inhibition or silencing of LOXL2 in other breast or
gastric carcinoma cells have been recently reported (Barry-
Hamilton et al, 2010; Peng et al, 2009). Despite the tumourigenic
differences, our present data support the positive influence ofwww.embomolmed.org EMBO Mol Med 3, 528–544LOXL2 in tumour recurrence and experimental lung metastasis
of MDA-MB-231 cells (Fig 6B–D).
Importantly, the IHC analyses performed with our home-
made antiserum (Fong et al, 2007) in a series of grade 3 human
breast IDC (n¼ 195) showed that increased LOXL2 expression
with a specific cytoplasmic/perinuclear pattern is significantly
associated with the basal-like subtype (Fig 7B; 57.4% tumours).
Noteworthy, the heterogeneous cytoplasmic/perinuclear stain-
ing of LOXL2 observed in basal-like tumours was similar to the
onewe previously reported in larynx squamous cell carcinomas,
which proved to be of prognostic value (Peinado et al, 2008),
and in a small series of breast adenocarcinomas (Hollosi et al,
2009). Moreover, the cytoplasmic/perinuclear LOXL2 pattern in
breast carcinomas was significantly associated with distant
metastasis incidence (Fig 7B and C), further supporting a role of
LOXL2 in metastatic dissemination of basal-like carcinomas.
These results are also in agreement with our previous
observation that LOXL2 overexpression is associated with poor
clinical outcome of N0 breast adenocarcinomas (Peinado et al,
2008) and with the association of increased LOXL2 transcripts
with metastasis incidence in the van de Vijver et al (2002) and
Wang et al (2005) series (Supporting Information Fig S2B), as
well as with ER- tumours from the NKI series recently reported
(Barker et al, 2011). No extensive data of LOXL2 protein
expression on breast tumours were so far available, since
previous IHC studies of LOXL2 were restricted to a few samples
of breast adenocarcinomas of non-specific histological subtypes
and lacking information of other clinico-pathological features
(Barry-Hamilton et al, 2010; Hollosi et al, 2009). Our present IHC
analyses in a large series of grade 3 breast tumours identify for
the first time the basal-like carcinomas as the breast tumour
subtype with highly significant expression of intracellular
LOXL2 protein associated with distant metastasis. Interestingly,
the LOXL2 expression detected in breast tumours with our
polyclonal antiserum is exclusively present in the tumour cells
but not in the stromal component (Fig 7A), supporting a likely
intracellular action of LOXL2 in metastasis. The staining of 32
basal-like tumours included in the present series with a
distinctly different antiserum (described in Barry-Hamilton
et al, 2010) corroborates the LOXL2 intracellular stain in about
22% of the cases. In addition, intracellular plus stromal stain
was detected in 44% of the cases (Supporting Information
Fig S9B), suggesting an additional extracellular action of LOXL2
in a subset of basal-like tumours, as supported from recent
studies in other tumour types (Barker et al, 2011; Barry-
Hamilton et al, 2010). Taken together, these results might
suggest a dual role and/or substrates for LOXL2 in regulating
intracellular and extracellular components that may prevail in
distinct pathological contexts or tumour subtypes. Indeed,
previous studies have indicated an important role for LOX in
hypoxia-induced metastasis (Erler et al, 2006) and the specific
participation of LOX in the establishment of the pre-metastatic
niche through extracellular matrix remodelling (Erler et al,
2009). A role for extracellular LOXL2 in the development of
pathological microenvironment and the effectiveness of anti-
LOXL2 antibody or copper chelator inhibitors in inhibition of
tumour or metastatic burden of carcinomaMDA-MB-435 cells or 2011 EMBO Molecular Medicine 539
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540in PyMT induced tumours has been recently reported (Barker
et al, 2011; Barry-Hamilton et al, 2010). Other recent studies
have also reported the participation of secreted LOXL2 in gastric
carcinoma metastasis (Peng et al, 2009). Further studies will
clarify the contribution of extracellular LOXL2 to the metastasis
potential of basal-like breast tumours.
We provide here new mechanistic insights into the action of
intracellular LOXL2 in the regulation of the mesenchymal and
migratory phenotype of basal-like carcinoma cells that may
likely underlie its metastatic potential. In agreement with the
reported induction of EMT by LOXL2 (Peinado et al, 2005), we
now report that LOXL2 silencing induces a MET process in
the human basal-like breast cell lines analysed. Interestingly,
the phenotypic change induced by LOXL2 silencing is associated
with downregulation of some mesenchymal markers and
increased expression of tight junction and cell polarity
components but without significant changes in E-cadherin
expression (Fig 2E, Supporting Information Fig S3B). Impor-
tantly, LOXL2 silencing in basal MDA-MB-231 cells induces the
expression and organization of tight junctions and Lgl2- and
Par3-containing cell polarity complexes at the upper lateral
membrane, indicating their functional organization as in ‘bona-
fide’ epithelial cells. The reverse situation occurs in MCF7-
LOXL2 cells, thus further supporting the implication of LOXL2 in
the absence/disorganization of tight junctions and cell polarity
complexes in breast carcinoma cells. Surprisingly, this situation
appears to occur independently of E-cadherin expression or
organization at cell–cell contacts. Since MDA-MB-231- and
BT549-shLOXL2 cells maintain elevated levels of N-cadherin
and cadherin11 (Fig 2G and Supporting Information Fig S4A),
we speculate that either of those cadherins may substitute for E-
cadherin in the maintenance of cell–cell contacts and collabo-
rate in the functional organization of tight junctions and cell
polarity complexes in the absence of LOXL2. In this regard, some
situations in which N-cadherin can replace E-cadherin, like in
the functional organization of embryonic intestinal epithelium,
have been recently reported (Libusova et al, 2010). Further
studies will contribute to clarify this interesting possibility.
Independent of this aspect, we present here evidence for a novel
mechanism of LOXL2mediated downregulation of tight junction
and cell polarity complexes at transcriptional level. LOXL2
significantly represses the activity of claudin1 and Lgl2
promoters and both the promoter activity and mRNA levels
of these genes are upregulated after LOXL2 silencing in basal
MDA-MB-231 cells (Fig 5A–C). The LOXL2 repressive action on
both promoters is independent of Snail1 and, interestingly, of
the LOXL2 catalytic domain (Fig 5D–F), suggesting a new role
of intracellular LOXL2 apart from its enzymatic activity. Our
previous studies also provided evidence for Snail1-dependent
and -independent pathways in LOXL2 function on EMT and
epidermal terminal differentiation of squamous carcinoma cells
(Peinado et al, 2008). The present data provide strong support
for a novel intracellular action of LOXL2, independent of Snail1,
in the downregulation of tight junction and cell polarity genes,
thus actively contributing to the maintenance of the mesench-
ymal phenotype of basal-like carcinoma cells. A role for
intracellular LOXL2 mediated by RAMP3 in tumourigenicity 2011 EMBO Molecular Medicineof MDA-MB-231 cells has been recently reported (Breckhman
et al, 2011). On the other hand, LOXL2 contributes positively to
activation of the FAK signaling pathway and participates in the
organization of focal adhesion complexes in basal carcinoma
cells in a pattern fully compatible with a motile phenotype (Fig 4
and Supporting Information Fig S5). Whether the influence of
LOXL2 on focal contacts is mediated by the extracellular
catalytically active form, as reported for FAK/Src signaling in
gastric carcinoma cells (Peng et al, 2009), or can be also
mediated by intracellular LOXL2 remains to be established in
future studies.
In summary, our present results define intracellular LOXL2 as
a new marker of basal-like breast tumours associated with
metastasis incidence and demonstrate its active participation in
lung metastatic dissemination of basal breast carcinoma cells.
The downregulation by LOXL2 of tight junction and cell polarity
components at transcriptional level unveil a new and unex-
pected molecular action for LOXL2 that can provide new targets
for anti-metastatic therapies of basal-like breast carcinomas.MATERIALS AND METHODS
Tumour samples
The present study was performed using a total of 202 infiltrating
ductal breast carcinoma (IDC) tumours acquired from the archives of
the Pathology Department of La Paz Hospital, Madrid, Spain and from
the MD Anderson Cancer Center Madrid, Madrid, Spain. All of the
tumours were grade 3. Patients underwent surgery between 2003
and 2004. The mean patient age at surgery was 56.3 years (range, 30–
81 years). In the microarrays analysis and qRT-PCR study we used a
total of 58 frozen specimens. The IHC analyses included all of the 202
IDC. According to the TNM Classification staging, 82 of the tumours
were stage I, 66 were stage II and 54 were stage III–IV. Histological
and IHC studies were all carried out on formalin-fixed, paraffin-
embedded tissue samples. Clinical data of the tumour sample are
provided in Supporting Information Table S2. This study was
performed following standard ethical procedures of the Spanish
regulation (Ley de Investigacio´n Orga´nica Biome´dica, 14 July 2007)
and was approved by the ethic committees of La Paz Hospital and
MD Anderson Cancer Center Madrid, Madrid, Spain.
Gene profiling of breast tumours
Microarray analyses on 58 frozen specimens were performed using
Human 1A Microarray (V2) G4110B (Agilent technologies). Details for
RNA extraction, probe synthesis, hybridization on oligonucleotide
arrays and statistical analyses are provided as Supporting Information.
Quantitative RT-PCR
cDNA from the different cell lines and tumour samples was obtained
from 1mg of total RNA using random primers and Superscript II
system (Life Technologies Inc.) as previously described (Moreno-Bueno
et al, 2009). Quantitative real-time PCR (TaqMan) was performed with
Iq5 BIORAD (BioRad Laboratories SA), using the manufacturer’s
recommended conditions. The comparative threshold cycle (Ct)
method was used to calculate the amplification factor as specified
by the manufacturer, and the amount of target and endogenousEMBO Mol Med 3, 528–544 www.embomolmed.org
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The paper explained
PROBLEM:
Basal-like carcinomas are highly aggressive tumours with
visceral metastasis, poor prognosis and a high tendency to
develop chemoresistance. Therapeutic targets for basal-like
carcinomas have not been yet defined hindering the treatment of
this specific breast tumour type. Basal-like tumours have been
identified as expressing a distinct set of EMT markers, being likely
candidates to suffer EMT. LOXL2, a member of the LOX family, has
been identified as an EMT regulator and as a prognostic marker in
SCC. We have investigated the role of LOXL2 in breast carcinomas.
RESULTS:
We define a basal-like signature in grade 3 breast IDC tumours
and detect LOXL2 overexpression in basal-like carcinomas. LOXL2
expression defines the basal-like tumours and is associated to
distant metastasis of breast tumours in several public datasets.
LOXL2 expression is restricted to breast carcinoma cell lines
with a basal-like phenotype showing a specific cytoplasmic/
perinuclear LOXL2 pattern. Knockdown of LOXL2 induces a MET
phenotype and suppresses lung metastasis dissemination of
basal carcinoma cells. We demonstrate that LOXL2 negatively
modulates the expression and organization of tight junctions and
cell polarity complexes, by transcriptional repression of tight
junction (claudin1) and cell polarity (Lgl2) genes independent of
Snail1. Analyses of LOXL2 in a large series of grade 3 breast IDC
show that intracellular LOXL2 stain is significantly associated
with basal-like tumours, and importantly, with distant meta-
static incidence of basal-like breast carcinomas.
IMPACT:
The data bring to light the importance of LOXL2 in basal-like
breast tumours and we propose intracellular LOXL2 as a new
marker of this aggressive breast carcinoma subtype. The LOXL2
implication in the downregulation of tight junction and cell
polarity components unveils a new and unexpected molecular
action for LOXL2 that can provide new targets for antimetastatic
therapies of basal-like breast carcinomas.reference was determined from a standard curve for each experi-
mental sample. The sequence of oligonucleotides and TaqMan probes
used for the analysis of LOXL2 were obtained using the Assays-by-
Design (SM) File Builder program (Applied Biosystems); a B2M probe
(Applied Biosystems) was used as endogenous gene control.
Immunohistochemical analysis
LOXL2 IHC staining was performed by the LSAB (Dako) method with a
heat-induced antigen retrieval step, as previously described (Moreno-
Bueno et al, 2009; Peinado et al, 2008). Briefly, sections were
immersed in boiling 10mM sodium citrate at pH 6.0 for 3min in a
pressure cooker. The rabbit polyclonal antisera against human LOXL2
were previously described and they are refered here as KC (Fong et al,
2007) and Arresto (Barry-Hamilton et al, 2010) antibodies. The
antibodies and conditions used for staining of basal and EMTmarkers
are described in Supporting Information Table S4. The primary
antibodies were omitted in the negative controls. LOXL2 staining
with our home-made antiserum was defined as intense cytoplasmic/
perinuclear when it was detected in at least 20% of tumour cells
when compared with the diffuse staining pattern detected in the
cytoplasm in most tumour cells (Peinado et al, 2008). LOXL2 staining
with Arresto antiserum was categorized as: negative, intracellular and
intracellular plus stromal. IHC analyses for ESR, PR, ErbB2 and EMT
markers were performed as previously described (Sarrio et al, 2008).
Cell cultures and transfection assays
Human breast carcinoma cell lines MCF7, MDA-MB-231, SkBR3,
BT474, BT549 and non-tumourigenic HBL100 cells were obtained
from the ATCC-LGC Promochem Partnership and were cultured
according to the indicated supplier conditions. The generation and
culture conditions of MCF7-LOXL2-V5 cells were previously describedwww.embomolmed.org EMBO Mol Med 3, 528–544(Hollosi et al, 2009). MDA-MB-231-TGL cells were kindly provided by
Dr. J. Massague´ (Memorial Sloan-Kettering Cancer Canter, New York)
and cultured as previously described (Minn et al, 2005). Cells were
maintained as monolayer cultures at 378C in an atmosphere with 5%
CO2. For generation of shLOXL2 and shEGFP cells, the indicated cell
lines were transfected with pSuper-shLOXL2 and pSuper-shEGFP
vectors, respectively, and independent clones isolated by selection in
the presence of puromycin (1mg/ml) for 2–3 weeks. Two independent
shLOXL2 sequences (Supporting Information Table S5a), obtained from
SuperArray (Qiagen), were tested in transient transfection assays and
shLOXL2-3, giving the most effective silencing (60% reduction of
LOXL2 protein level) was used for stable transfections. pSuper-shEGFP
has been previously described (Olmeda et al, 2007).
Proliferation, migration and invasion assays
Details for proliferation, barrier migration and invasion in collagen IV
transwells assays are provided as Supporting Information.
Tumourigenesis and spontaneous metastasis assays
Control MDA-MB-231-shEGPP and MDA-MB-231-shLOXL2 cells from
subconfluent cultures were orthotopically injected (1106 in 0.05ml
serum free growth medium) into the left fifth mammary fat pad of
female Balb/c immunocompromised mice, aged 8 weeks (Charles
River) as described (Olmeda et al, 2007). Tumour growth was
measured twice a week by determination of the two orthogonal
external diameters using a caliper. When tumours reached a size of
0.7 cm3 they were surgically excised and processed for histology. A
minimum of four tumours from each cell line were generated. For
spontaneous metastasis assay, primary tumours were excised when
reached 0.4 cm3 volume. Afterwards, mice were left alive for additional
4 months and then sacrificed. Mice were housed and maintained 2011 EMBO Molecular Medicine 541
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542under specific pathogen-free conditions and used in accordance with
institutional guidelines and approved by the Use Committee for
Animal Care from the Universidad Auto´noma de Madrid (UAM).
Experimental metastasis assays and bioluminescence
imaging
Control MDA-MB-231-TGL-shEGFP and MDA-MB-231-TGL-shLOXL2
cells from subconfluent cultures were injected (1106 in 0.05ml
serum free growth medium) into the tail vein of female Balb/c
immunocompromised mice, aged 8 weeks (Charles River). For in vivo
bioluminescence imaging, mice were anesthetized and injected retro-
orbitally with 1.5mg of d-luciferin (15mg/ml in PBS). Imaging was
completed between 2 and 5min after injection with a Xenogen IVIS
(IVISR Lumina II) system coupled to Living Image acquisition and
analysis software (Xenogen Corporation). For bioluminescence in-
tensity (BLI) plots, photon flux was calculated as described (Minn et al,
2005). Measurements were performed once a week starting 3 weeks
after tail vein injection and up to 9 (control) and 12 (experimental)
weeks. Mice were housed and maintained under specific pathogen-
free conditions and used in accordance with institutional guidelines
and approved by the Use Committee for Animal Care from the
Universidad Auto´noma de Madrid (UAM).
Immunofluorescence and western blots
Western blots and immunofluoresce analyses were performed
basically as described (Moreno-Bueno et al, 2009) on cell extracts
and cells grown on cover slips and fixed on methanol or formaldehyde,
respectively. Details for antibodies and confocal imaging are provided
as Supporting Information and in Supporting Information Table S4.
Promoter assays
Promoter assays were performed basically as described (Peinado et al,
2005), using the human claudin1 promoter (82/þ236) (Martinez-
Estrada et al, 2006) and two human Lgl2 promoters (p672:244/
þ135; p673:743/þ135) (Spaderna et al, 2008) (kindly provided by
T. Brabletz, Freiburg University), in the indicated cell lines in the
presence or absence of the indicated amounts of wild type LOXL2,
Snail1 and/or DLOXL2. Generation of DLOXL2 mutant (carrying an
internal deletion from 558 to 688 aa) and details for transfection
efficiency and quantification are provided as Supporting Information.
Statistical analysis
The Chi-square contingency test Yates correction, or Fisher’s exact test,
was used to determine the statistical significance of the relationships
between IHC and clinico-pathological features. Values of p<0.05 were
considered statistically significant. These analyses were carried out
using the SPSS 17.0 for statistical program (SPSS Inc.).Author contributions
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